Galera Therapeutics Stock Fundamentals
Galera Therapeutics fundamentals help investors to digest information that contributes to Galera Therapeutics' financial success or failures. It also enables traders to predict the movement of Galera Pink Sheet. The fundamental analysis module provides a way to measure Galera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Galera Therapeutics pink sheet.
Galera |
Galera Therapeutics Company Current Valuation Analysis
Galera Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Galera Therapeutics Current Valuation | 146.68 M |
Most of Galera Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Galera Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Galera Therapeutics has a Current Valuation of 146.68 M. This is 98.98% lower than that of the Biotechnology sector and 96.84% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.12% higher than that of the company.
Galera Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Galera Therapeutics's current stock value. Our valuation model uses many indicators to compare Galera Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Galera Therapeutics competition to find correlations between indicators driving Galera Therapeutics's intrinsic value. More Info.Galera Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Galera Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Galera Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Galera Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galera Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Galera Therapeutics could also be used in its relative valuation, which is a method of valuing Galera Therapeutics by comparing valuation metrics of similar companies.Galera Therapeutics is currently under evaluation in current valuation category among its peers.
Galera Fundamentals
| Return On Equity | -10.63 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 146.68 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Shares Owned By Insiders | 36.15 % | ||||
| Shares Owned By Institutions | 18.95 % | ||||
| Number Of Shares Shorted | 2.12 M | ||||
| Price To Earning | (0.78) X | ||||
| Price To Book | 29.39 X | ||||
| EBITDA | (46.69 M) | ||||
| Net Income | (59.08 M) | ||||
| Cash And Equivalents | 52.01 M | ||||
| Cash Per Share | 1.94 X | ||||
| Total Debt | 152.3 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 5.02 X | ||||
| Book Value Per Share | (2.48) X | ||||
| Cash Flow From Operations | (44.85 M) | ||||
| Short Ratio | 1.16 X | ||||
| Earnings Per Share | (0.91) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 0.5 | ||||
| Beta | 2.03 | ||||
| Market Capitalization | 7.89 M | ||||
| Total Asset | 26.14 M | ||||
| Retained Earnings | (437.41 M) | ||||
| Working Capital | 16.67 M | ||||
| Current Asset | 36.65 M | ||||
| Current Liabilities | 5.37 M | ||||
| Net Asset | 26.14 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Galera Pink Sheet
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Global Correlations Find global opportunities by holding instruments from different markets |